2012
DOI: 10.1117/12.2000624
|View full text |Cite
|
Sign up to set email alerts
|

Tunable photonic structures from liquid crystal elastomers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
5

Relationship

4
1

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 0 publications
0
5
0
Order By: Relevance
“…They can affect the amplitude as well as the phase of an optical field [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. One of their advantageous properties is tunability, which can be obtained by the application of external stimuli, such as electric [ 4 , 10 , 11 , 12 , 13 ], magnetic [ 14 , 15 , 16 , 17 ], and mechanical or optical fields [ 18 , 19 , 20 ].…”
Section: Introductionmentioning
confidence: 99%
“…They can affect the amplitude as well as the phase of an optical field [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. One of their advantageous properties is tunability, which can be obtained by the application of external stimuli, such as electric [ 4 , 10 , 11 , 12 , 13 ], magnetic [ 14 , 15 , 16 , 17 ], and mechanical or optical fields [ 18 , 19 , 20 ].…”
Section: Introductionmentioning
confidence: 99%
“…Another interesting property of azo‐containing LCEs is their huge opto‐optical response, which is associated with huge light‐induced modifications of the optical refractive index, that appear due to collective response of the LCE medium to the trans‐ to‐ cis photoisomerization process. For that reason optical patterning of LCEs provides simple fabrication of tunable optical diffraction structures (volume holograms) that can easily be manipulated by external strain and/or temperature variations …”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, a sequence-and time-dependent synergism between NGR-hTNF and chemotherapy was observed when the former was administered 2 hours before the latter [7,8]. Phase I trials selected NGR-hTNF 0.8 µg/m 2 as the optimal dose in monotherapy [9] and in combination with doxorubicin [10], based on dynamic imaging changes, soluble TNF-receptors kinetics, and tolerability. In this singlearm phase II trial, the addition of NGR-hTNF 0.8 µg/m 2 to doxorubicin 75 mg/m 2 was associated with a manageable toxicity profile and similar antitumor activity in platinumresistant and platinum-sensitive patients.…”
Section: Discussionmentioning
confidence: 99%